Sofosbuvir/velpatasvir - Gilead Sciences

Drug Profile

Sofosbuvir/velpatasvir - Gilead Sciences

Alternative Names: Epclusa; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvir

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 07 Feb 2018 Gilead Sciences completes a phase III trial in Hepatitis C (Treatment-naive, Treatment-experienced) in India (PO) (NCT03074331)
  • 16 Jan 2018 Gilead Sciences completes a phase II trial for Hepatitis C in New Zealand (PO) (NCT02728206)
  • 07 Dec 2017 Phase-I clinical trials in Hepatitis C (In volunteers) in USA (PO, Granules) (EudraCT2017-004044-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top